Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Brian Dolinski"'
Autor:
Manfred Kraus, Yuxun Wang, Dan Aleksandrowicz, Eric Bachman, Alexander A Szewczak, Deborah Walker, Lin Xu, Melaney Bouthillette, Kaleen M Childers, Brian Dolinski, Andrew M Haidle, Johnny Kopinja, Linda Lee, Jongwon Lim, Kevin D Little, Yanhong Ma, Anjili Mathur, Jan-Rung Mo, Erin O'Hare, Ryan D Otte, Brandon M Taoka, Wenxian Wang, Hong Yin, Anna A Zabierek, Weisheng Zhang, Shuxia Zhao, Joe Zhu, Jonathan R Young, C Gary Marshall
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e37207 (2012)
A high percentage of patients with the myeloproliferative disorder polycythemia vera (PV) harbor a Val617→Phe activating mutation in the Janus kinase 2 (JAK2) gene, and both cell culture and mouse models have established a functional role for this
Externí odkaz:
https://doaj.org/article/e1af821b8d2243da83151c870eaab2ae
Autor:
Yan Wang, Erick J. Morris, Richard E. Middleton, Paul T. Kirschmeier, Leigh Zawel, Cynthia Seidel-Dugan, Pasi A. Jánne, Kwok-Kin Wong, Kumiko Nagashima, Heather Hirsch, Steven Ripley, Chris Hulton, Weiqun Zhang, Rossana Chung, Stephen Wu, Peter Strack, Thi T. Nguyen, Brian Dolinski, Jongwon Lim, Rafael Fernandez, Haiyan Yan, Qi Pan, Asli Muvaffak
PDF file - 1334KB, S1. IC50 values of TBK1 inhibitors Compound number 5, Compound number 4 and Compound number 3 from the selected PDAC, colorectal cancer and NSCLC cancer cell lines using are shown. Table 1S. List of shRNAs Targeting TBK1 Table 2S.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98442b5d4353d94a24d08eb4fa097ec2
https://doi.org/10.1158/1541-7786.22511083
https://doi.org/10.1158/1541-7786.22511083
Autor:
Manfred Kraus, Jannik N. Andersen, Peter Blume-Jensen, Nancy Kohl, Victoria Richon, Giulio Draetta, Martin L. Scott, Roderick T. Bronson, Shailaja Kasibhatla, Ekaterina V. Bobkova, Alan Northrup, Thomas F. Vogt, Myung K. Shin, Melissa Hurd, Paula Andrade, Erica Leccese, Minilik Angagaw, Nirah H. Shomer, Diana Gargano, Alessandra Di Bacco, Yusuf Erkul, Erin O'Hare, Kumiko Nagashima, Kun Hu, Yamicia Connor, Brian Dolinski, Kaiko Kunii, Heike Keilhack, Katharine Ellwood-Yen
Supplementary Figures 1-4 from PDK1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::828919a62a5a02040e157eb5ac219fb4
https://doi.org/10.1158/0008-5472.22390089
https://doi.org/10.1158/0008-5472.22390089
Autor:
Jesse Green, Adam Johnson, Brian Granger, Ouwen Liang, Jesus Moreno, Andrew Tucker, Hallee Wright, Brian Dolinski, Hanane Ennajdaoui, Semih Tareen, Neal van Hoeven, PhD, Jagesh Shah, Kutlu Elpek, Aaron Foster, Terry J. Fry
Publikováno v:
Blood. 140:7768-7769
Autor:
Youyuan Xu, Cloud P. Paweletz, Maciej Wiznerowicz, Victoria M. Richon, Sanjeev Munshi, Brian Dolinski, Kumiko Nagashima, Anke Klippel, Sujal V. Deshmukh, Peter Blume-Jensen, Bo-Sheng Pan, Jannik N. Andersen, Alan B. Northrup, Timothy Allison, Alexander A. Szewczak, Zangwei Xu, Manfred Kraus, Heike Keilhack, Sriram Sathyanarayanan, Youwei Yan, Albert H. Y. Chen, Uwe Mueller, Lixia Li, An Chi, Thi D.T. Nguyen, Ekaterina V. Bobkova, Roy M. Pollock, Bart Lutterbach, Stuart D. Shumway
Publikováno v:
Journal of Biological Chemistry. 286:6433-6448
Phosphoinositide-dependent kinase 1 (PDK1) is a critical activator of multiple prosurvival and oncogenic protein kinases and has garnered considerable interest as an oncology drug target. Despite progress characterizing PDK1 as a therapeutic target,
Autor:
Carlo Toniatti, Ronan C. O'Hagan, Paula Andrade, Apryle M Kuznicki, Cem Elbi, Sybil M. G. Williams, Brian Dolinski
Publikováno v:
Cancer Cell International
Background Cells with homologous recombination (HR) deficiency, most notably caused by mutations in the BRCA1 or BRCA2 genes, are sensitive to PARP inhibition. Microsatellite instability (MSI) accounts for 10-15% of colorectal cancer (CRC) and is hyp
Autor:
Devendra P. Dubey, Chester A. Alper, Katherine Cosmopoulos, Lennart Truedsson, Rosanne Stein, Gunnar Sturfelt, Gabriel Uko, Brian Dolinski, Charles E. Larsen, Peter Densen, Anders G. Sjöholm, Jianhua Xu
Publikováno v:
Journal of Clinical Immunology. 23:297-305
About 25% of C2-deficient homozygotes have increased susceptibility to severe bacterial infections. C2-deficient homozygotes had significantly lower serum levels of IgG2, IgG4, IgD, and Factor B, significantly higher levels of IgA and IgG3 and levels
Autor:
Adrian Whitty, R. Blake Pepinsky, Russell B. Lingham, Richard A. Mumford, Gail Van Riper, Linda L. Chang, Dennis C. Dean, William K. Hagmann, Suzanne E Amo, Ling Ling Chen, Qian Si, Conrad E. Raab, Roy R Lobb, Diane Leone, Brian Dolinski
Publikováno v:
Biochemistry. 41:7125-7141
Integrins alpha9beta1 and alpha4beta1 form a distinct structural class, but while alpha4beta1 has been subjected to extensive study, alpha9beta1 remains poorly characterized. We have used the small molecule N-(benzenesulfonyl)-(L)-prolyl-(L)-O-(1-pyr
Autor:
Peter Strack, Jongwon Lim, Richard E. Middleton, Thi T. Nguyen, Cynthia Seidel-Dugan, Yan Wang, Kumiko Nagashima, Brian Dolinski, Kwok-Kin Wong, Rafael Fernandez, Stephen Wu, Rossana Chung, Haiyan Yan, Asli Muvaffak, Chris Hulton, Steven Ripley, Qi Pan, Heather Hirsch, Erick J. Morris, Leigh Zawel, Paul Kirschmeier, Pasi A. Jänne, Weiqun Zhang
Publikováno v:
Molecular cancer research : MCR. 12(7)
TBK1 (TANK-binding kinase 1) is a noncanonical IκB protein kinase that phosphorylates and activates downstream targets such as IRF3 and c-Rel and, mediates NF-κB activation in cancer. Previous reports demonstrated synthetic lethality of TBK1 with m
Autor:
Mark Ayers, Brian Long, Rebecca L. Blanchard, Andrey Loboda, Eun Kyung Im, Gary Gilliland, Nathan R. Miselis, Minilik Angagaw, Junghoon Lee, Vincenzo Pucci, Anna Georgieva Kondic, Alwin Schuller, Yaolin Wang, Carrie E. Merkel, Brian Dolinski, Peter Strack, Lauren Harmonay, Theresa Zhang, Michael Nebozhyn, Xianlu Q. Lennon, Ali-Samer Al-Assaad, James W. Monahan, Bin Shi, Harold Hatch, Leigh Zawel, David J. Mauro, Heather Hirsch, Robert Booher, Stephen Fawell, Thi D.T. Nguyen
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e108371 (2014)
PLoS ONE
PLoS ONE
Dinaciclib is a potent CDK1, 2, 5 and 9 inhibitor being developed for the treatment of cancer. Additional understanding of antitumor mechanisms and identification of predictive biomarkers are important for its clinical development. Here we demonstrat